

115TH CONGRESS
1ST SESSION

S. 849

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 7, 2017

Referred to the Committee on Energy and Commerce

AN ACT

To support programs for mosquito-borne and other vector-borne disease surveillance and control.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Strengthening Mos-
3 quito Abatement for Safety and Health Act” or the
4 “SMASH Act”.

5 **SEC. 2. REAUTHORIZATION OF MOSQUITO ABATEMENT FOR**

6 **SAFETY AND HEALTH PROGRAM.**

7 Section 317S of the Public Health Service Act (42
8 U.S.C. 247b–21) is amended—

9 (1) in subsection (a)(1)(B)—

10 (A) by inserting “including programs to
11 address emerging infectious mosquito-borne dis-
12 eases,” after “control programs,”; and

13 (B) by inserting “or improving existing
14 control programs” before the period at the end;

15 (2) in subsection (b)—

16 (A) in paragraph (1), by inserting “, in-
17 cluding improvement,” after “operation”;

18 (B) in paragraph (2)—

19 (i) in subparagraph (A)—

20 (I) in clause (ii), by striking “or”
21 at the end;

22 (II) in clause (iii), by striking the
23 semicolon at the end and inserting “,
24 including an emerging infectious mos-
25 quito-borne disease that presents a se-
26 rious public health threat; or”; and

(III) by adding at the end the following:

3 “(iv) a public health emergency due to
4 the incidence or prevalence of a mosquito-
5 borne disease that presents a serious pub-
6 lic health threat.”; and

14 (C) in paragraph (4)(C), by striking “that
15 extraordinary” and all that follows through the
16 period at the end and inserting “that—

1 “(I) the size or density of the po-
2 tentially impacted human population;

3 “(II) the size or density of a
4 mosquito population that requires
5 heightened control; or

6 “(III) the severity of the mos-
7 quito-borne disease, such that ex-
8 pected serious adverse health out-
9 comes for the human population jus-
10 tify the waiver.”; and

11 (D) by amending paragraph (6) to read as
12 follows:

13 “(6) NUMBER OF GRANTS.—A political subdivi-
14 sion or a consortium of political subdivisions may
15 not receive more than one grant under paragraph
16 (1).”; and

17 (3) in subsection (f)—

18 (A) in paragraph (1), by striking “for fis-
19 cal year 2003, and such sums as may be nec-
20 essary for each of fiscal years 2004 through
21 2007” and inserting “for each of fiscal years
22 2018 through 2022”;

23 (B) in paragraph (2), by striking “the
24 Public Health Security and Bioterrorism Pre-
25 paredness and Response Act of 2002” and in-

1 serting “other medical and public health pre-
2 paredness and response laws”; and
3 (C) in paragraph (3)—
4 (i) in the heading, by striking “2004”
5 and inserting “2018”; and
6 (ii) by striking “2004” and inserting
7 “2018”.

8 **SEC. 3. EPIDEMIOLOGY-LABORATORY CAPACITY GRANTS.**

9 Section 2821 of the Public Health Service Act (42
10 U.S.C. 300hh–31) is amended—
11 (1) in subsection (a)(1), by inserting “, includ-
12 ing mosquito and other vector-borne diseases,” after
13 “infectious diseases”; and
14 (2) in subsection (b), by striking “2010 through
15 2013” and inserting “2018 through 2022”.

16 **SEC. 4. GAO STUDY.**

17 (a) STUDY.—The Comptroller General of the United
18 States shall conduct a study on the state of surveillance
19 and control of mosquito-borne infectious diseases in the
20 United States and territories, including the state of pre-
21 paredness for conducting such surveillance and control.

22 The study shall include—

23 (1) a description of the infrastructure and pro-
24 grams for mosquito control in the United States, in-
25 cluding—

23 (4) any regulatory challenges for developing and
24 utilizing vector-control technologies and platforms as
25 part of mosquito control strategies.

1 (b) CONSULTATIONS.—In conducting the study under
2 subsection (a), the Comptroller General of the United
3 States shall consult with—

4 (1) State and local public health officials in-
5 volved in mosquito and other vector-borne disease
6 surveillance and control efforts;

7 (2) researchers and manufacturers of mosquito
8 control products;

9 (3) stakeholders involved in mosquito abate-
10 ment activities;

11 (4) infectious disease experts; and

12 (5) entomologists involved in mosquito-borne
13 disease surveillance and control efforts.

14 (c) REPORT.—Not later than 18 months after the
15 date of enactment of this Act, the Comptroller General
16 of the United States shall submit to the Committee on
17 Health, Education, Labor, and Pensions of the Senate and
18 the Committee on Energy and Commerce of the House
19 of Representatives a report containing the results of the
20 study conducted under subsection (a) and relevant

- 1 recommendations for Zika virus and other mosquito-borne
- 2 diseases preparedness and response efforts.

Passed the Senate September 6, 2017.

Attest:

JULIE E. ADAMS,

Secretary.